Novi and Eli Lilly in fierce competition

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

PUBLISHED TUE, MAR 31 20267:39 AM EDTUPDATED TUE, MAR 31 20262:10 PM EDT

Annika Kim Constantino@ANNIKAKIMC

SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email

KEY POINTS

• Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, “predictable” monthly prices. 

• Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name.

• Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as high as $600 a year on the pill.

In this article

• NVO-0.02 (-0.07%)

• HIMS+0.39 (+1.88%)

• LLY+5.43 (+0.59%)

Follow your favorite stocksCREATE FREE ACCOUNT